BRPI0607579A2 - uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer - Google Patents
uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncerInfo
- Publication number
- BRPI0607579A2 BRPI0607579A2 BRPI0607579-7A BRPI0607579A BRPI0607579A2 BR PI0607579 A2 BRPI0607579 A2 BR PI0607579A2 BR PI0607579 A BRPI0607579 A BR PI0607579A BR PI0607579 A2 BRPI0607579 A2 BR PI0607579A2
- Authority
- BR
- Brazil
- Prior art keywords
- indolinone
- compound
- ctla4
- antibody
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- -1 5-fluoro-2-oxo-1,2-dihydro-3H- indol-3-ylidene Chemical group 0.000 abstract 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229960005386 ipilimumab Drugs 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 abstract 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 229940126214 compound 3 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 208000037819 metastatic cancer Diseases 0.000 abstract 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66465305P | 2005-03-23 | 2005-03-23 | |
| PCT/US2006/007651 WO2006101692A1 (en) | 2005-03-23 | 2006-03-03 | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607579A2 true BRPI0607579A2 (pt) | 2009-09-15 |
Family
ID=36680342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607579-7A BRPI0607579A2 (pt) | 2005-03-23 | 2006-03-03 | uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer |
Country Status (16)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007034327A1 (en) * | 2005-09-20 | 2007-03-29 | Pfizer Products Inc. | Dosage forms and methods of treatment using a tyrosine kinase inhibitor |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US20080206235A1 (en) * | 2006-12-27 | 2008-08-28 | Johns Hopkins University | Compositions and methods for stimulating an immune response |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| DK2769737T3 (en) * | 2009-07-20 | 2017-07-24 | Bristol Myers Squibb Co | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES |
| EP2949671A1 (en) * | 2009-10-12 | 2015-12-02 | Pfizer Inc | Cancer treatment |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| KR20140038382A (ko) | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 |
| SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| EA037351B8 (ru) | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| WO2014182761A1 (en) * | 2013-05-09 | 2014-11-13 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| AU2015300006B2 (en) * | 2014-08-07 | 2018-08-30 | Haruki Okamura | Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody |
| DK3186281T3 (da) | 2014-08-28 | 2019-06-11 | Halozyme Inc | Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor |
| PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
| EP4151231A1 (en) * | 2015-02-13 | 2023-03-22 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| WO2016161347A1 (en) * | 2015-04-03 | 2016-10-06 | Pharmacyclics Llc | Combinations for generating tumor-specific immunological memory |
| PL3319635T3 (pl) | 2015-06-24 | 2021-10-25 | Immodulon Therapeutics Limited | Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej |
| EP3347380B1 (en) | 2015-09-11 | 2024-09-25 | Nascent Biotech, Inc. | Enhanced delivery of drugs to the brain |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| MX2019013648A (es) | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| EP3902833A2 (en) | 2018-12-26 | 2021-11-03 | City of Hope | Activatable masked anti-ctla4 binding proteins |
| KR102371980B1 (ko) | 2020-06-29 | 2022-03-08 | 인하대학교 산학협력단 | 췌장암 예방 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US6051227A (en) * | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) * | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) * | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US7109003B2 (en) * | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| MXPA02008021A (es) * | 2000-02-15 | 2004-04-05 | Sugen Inc | Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas. |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| JP2006500931A (ja) * | 2002-09-30 | 2006-01-12 | ファイザー・プロダクツ・インク | 高レベルのヒト配列抗体を産生するハイブリドーマ |
| AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
| CA2540639C (en) * | 2003-10-02 | 2010-08-31 | Pharmacia & Upjohn Company Llc | Salts and polymorphs of a pyrrole-substituted indolinone compound |
| US20050182122A1 (en) * | 2003-11-20 | 2005-08-18 | Bello Carlo L. | Method of treating abnormal cell growth using indolinone compounds |
| KR100845354B1 (ko) * | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항－ｃｔｌａ－4 항체의 용도 |
-
2006
- 2006-03-03 AU AU2006227880A patent/AU2006227880A1/en not_active Abandoned
- 2006-03-03 NZ NZ561138A patent/NZ561138A/en not_active IP Right Cessation
- 2006-03-03 KR KR1020077021665A patent/KR20070104673A/ko not_active Ceased
- 2006-03-03 EP EP06736897A patent/EP1863532A1/en not_active Withdrawn
- 2006-03-03 MX MX2007011767A patent/MX2007011767A/es unknown
- 2006-03-03 BR BRPI0607579-7A patent/BRPI0607579A2/pt not_active IP Right Cessation
- 2006-03-03 CA CA002602316A patent/CA2602316A1/en not_active Abandoned
- 2006-03-03 WO PCT/US2006/007651 patent/WO2006101692A1/en not_active Ceased
- 2006-03-03 CN CNA2006800096169A patent/CN101146553A/zh active Pending
- 2006-03-03 US US11/817,395 patent/US20090074787A1/en not_active Abandoned
- 2006-03-03 RU RU2007135167/14A patent/RU2007135167A/ru unknown
- 2006-03-10 AR AR20060100918A patent/AR054237A1/es unknown
- 2006-03-10 TW TW095108280A patent/TW200700083A/zh unknown
- 2006-03-13 JP JP2006068066A patent/JP2006265245A/ja not_active Withdrawn
-
2007
- 2007-08-23 IL IL185491A patent/IL185491A0/en unknown
- 2007-09-18 ZA ZA200708026A patent/ZA200708026B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200708026B (en) | 2008-11-26 |
| CN101146553A (zh) | 2008-03-19 |
| TW200700083A (en) | 2007-01-01 |
| KR20070104673A (ko) | 2007-10-26 |
| JP2006265245A (ja) | 2006-10-05 |
| US20090074787A1 (en) | 2009-03-19 |
| AR054237A1 (es) | 2007-06-13 |
| AU2006227880A1 (en) | 2006-09-28 |
| NZ561138A (en) | 2009-06-26 |
| WO2006101692A1 (en) | 2006-09-28 |
| MX2007011767A (es) | 2007-10-18 |
| CA2602316A1 (en) | 2006-09-28 |
| IL185491A0 (en) | 2008-01-06 |
| EP1863532A1 (en) | 2007-12-12 |
| RU2007135167A (ru) | 2009-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607579A2 (pt) | uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer | |
| Arany et al. | Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells | |
| Yan et al. | Aurora‐A kinase: a potent oncogene and target for cancer therapy | |
| Daud et al. | Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors | |
| Larkin et al. | Epothilones in the treatment of cancer | |
| Adams et al. | Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors | |
| Croom et al. | Imatinib mesylate: in the treatment of gastrointestinal stromal tumours | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| Prochazka et al. | Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to α-tocopheryl succinate | |
| TW200801042A (en) | Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment | |
| EA200602196A1 (ru) | Производные пиразола, композиции, содержащие эти соединения, и способы применения | |
| JP2006265245A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0519656A2 (pt) | terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida | |
| Haney et al. | Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma | |
| Shen et al. | Metabolic reprogramming in melanoma therapy | |
| WO2007016228A3 (en) | 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors | |
| Björklund et al. | Resveratrol induces SIRT1-and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment | |
| Bao et al. | Induction of overexpression of the 27-and 70-kDa heat shock proteins by bicyclol attenuates concanavalin A-induced liver injury through suppression of nuclear factor-κB in mice | |
| Tamegai et al. | Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites | |
| DE60008590D1 (de) | Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern | |
| Hudes | Signaling inhibitors in the treatment of prostate cancer | |
| EP1908826A4 (en) | PEPTIDE DERIVED FROM PROTEIN IN CONNECTION WITH PROSTATE AS A CANCER VACCINE CANDIDATE FOR A HLA-A3 SUPER-TYPE ALLELLE MOLECULE-POSITIVE PROSTATE AGENT | |
| Garattini | New approaches to cancer therapy | |
| Katsoulas et al. | Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl | |
| O'Hare et al. | Toward a cure for chronic myeloid leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |